Operational Team

DR. SELLAMUTHU SG CHIEF SCIENTIST AND PRODUCTION HEAD

Dr. Sellamuthu has more than ten years of experience in the biopharma/biologics, tissue and cell banking, development of adoptive cell (stem cell and adoptive immune cells) therapies for regenerative medicine and oversees product development and manufacturing. Since his joining with NiSCELL in 2013, he leads research and early development, overseeing the advancement of promising programs, technologies and assets across all therapeutic areas, from discovery through proof-of-concept. Dr. Sellamuthu has developed and optimized culture protocols for various type of stem cells (Mesenchymal Stem Cells from Bone marrow, umbilical cord tissue, heart biopsy) and immune cells (Natural Killer Cells and T-cells). He has published more than 20 research articles relevant to regenerative medicine involving in vitro, human trials and peer-reviewed journals. He also works closely with business development team, clinicians and with share holders to identify external sources of innovation.

Prior to joining NiSCELL in 2013, Dr. Sellamuthu spent more than three years in US to complete his doctorate program, while completing his key training in stem cell based therapy in the University of Utah, USA.

Born and educated in Chennai, India, Dr. Sellamuthu earned his bachelor’s degree in Biochemistry from University of Bharathiyar University, India in 2003; Master of Biochemistry from Bharathidasan University, India in 2005, Biotechnology from Sathyabama University, India in 2017 and Diploma in Bioinformatics from Bharathidasan University in 2004. Dr. Sellamuthu earned his Doctor of philosophy in the field of Regenerative medicine from University of Madras in 2014.

FARAH DALILA MOHD ZAIN QUALITY ASSURANCE ASSISTANCE MANAGER & REGULATORY SCIENCE OFFICER

Farah Dalila Mohd Zain began her career at NiSCELL in 2015, and has served as a Quality Assistant for more than 7 years. Farah has been leading the Quality Assurance department and supports internal audits, and coordinates and support external audits by the local authorities of National Pharmaceutical Regulatory Agency (NPRA) and Ministry of Health (MOH), Malaysia.

Farah plays primary role if in quality assurance department and leading the department to oversee the testing of a clinical grade product and service to ensure adherence to industry and the organization's standards. She involves directly in creating risk mitigation strategies for the sterile clinical grade products, and liaising with the production team in suggesting process improvements to enhance quality, management of QMS and Clean room facility. She had attended and completed her certification on International Good Manufacturing Practices, Quality Management System and GMP for Pharmaceutical Operations in 2017.

In her previous organization, Farah held researcher role for more than a year and had explored research activities for synthesis of morphine using Ketum leaves in 2012 at Drug centre USM, Pulau Pinang. She has also earned more than 4 years of experience in quality control requirements for pharmaceutical products 2012-2015.

Born and educated in Kedah, Malaysia, Farah has earned her Diploma in Science 2010 and Bachelors of Science (Hon) Chemistry (Forensic Analysis) Biology from University Technology MARA, Malaysia in 2012.

EZZATI RADZUAN QUALITY CONTROL ASSISTANT & FLOW CYTOMETRY EXPERT

Ezzati Radzuan began her career at NiSCELL in 2014, and has served as a Quality Control Assistant for more than 8 years and since 2014 she has been fully leading the Quality Control division and was promoted into roles of increasing responsibility and managing internal audits, supplier audits and coordinate and support external audits by the local authorities of National Pharmaceutical Regulatory Agency (NPRA) and Ministry of Health (MOH), Malaysia.

She has also been leading as a subject matter expert in the area of Flow Cytometry analysis for cellular product (Natural killer cells, T cells, Mesenchymal Stem Cells from various tissue origins). Her skills contribute to meet NiSCELL’s goal to produce cellular product with highest quality and purity for research and development and for pre-clinical applications. She had attended and completed her certification on International Good Manufacturing Practices, Quality Management System and GMP for Pharmaceutical Operations in 2017.

Born and educated in Perak, Malaysia, Ezzati earned her Diploma and Bachelors degree in Biology (majoring in molecular biology) from University Technology MARA, Malaysia in 2014.

SUSMITA KUMARASON RESEARCH SCIENTIST

Susmita, our young-talent scientist, has more than 4 years of experience working with stem cells, both professionally and academically. She has worked with stem cells of various sources, which includes induced Pluripotent Stem Cells (iPSCs), Embryonic Stem Cell, 3D Neural Stem Cells and predominantly Mesenchymal Stem Cells.

Susmita, along with the scientific team, manages research and development, pre-clinical trials and clinical trials. She has been a part of the research and development team and extends immense support for in vitro cell isolation, cell expansion and analysis for all cellular products such Natural killer cells, T cells, Mesenchymal Stem Cells from various tissue origins developed at NiSCELL. Her skills contribute to meet NiSCELL’s goal to produce cellular product with highest quality, purity, strength and potency for research and development and for pre-clinical applications.

Susmita received her First-Class Distinction BSc in Biotechnology from Amrita University. She then pursued her MSc in Advanced Biological Sciences at University of Liverpool. She has been extensively involved in academic related stem cell projects making her proficient in molecular biology lab and stem cell culture techniques. She has worked on the role of soluble factors and extracellular matrices in regulating cardiomyocyte differentiation from iPSCs. During her postgrad, she attempted to model cellular therapies for Hirschsprung’s disease using Neural Stem Cells. She also determined the best postnatal age to isolate and differentiate progenitor stem cells to obtain the highest proportions of neuronal and neuroglial marker-positive cells.